CelularityCELU -9.16%31 Days Payable is 315.61 as of Dec. 2025, which is 7% below its 10-year median of 338.47. GuruFocus rates CELU with a GF Score™ of 31/100 and a GF Value™ of $2.28 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 699 Biotechnology companies, Celularity ranks better than 77.68% on this metric.
Celularity's average Accounts Payable for the
three
months ended in Dec. 2025 was $25.50 Mil. Celularity's Cost of Goods Sold for the
three
months ended in Dec. 2025 was $7.37 Mil.
Hence, Celularity's Days Payable for the
three
months ended in Dec. 2025 was 315.61.
The historical rank and industry rank for Celularity's Days Payable or its related term are showing as below:
CELU'
s Days Payable Range Over the Past 10 Years
Min: 140.39 Med: 338.47 Max: 455.85
Current: 443.72
During the past 6 years, Celularity's highest Days Payable was 455.85. The lowest was 140.39. And the median was 338.47.
CELU's Days Payable is ranked better than 77.68% of 699
companies
in the Biotechnology industry
Industry Median: 112.84
vs CELU: 443.72
Celularity's Days Payable
increased
from Dec. 2024 (240.43) to Dec. 2025 (315.61).
It may suggest that Celularitydelayed paying its suppliers.
Celularity Days Payable Related Terms
Celularity Days Payable Historical Data
* Premium members only.
The historical data trend for Celularity's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Celularity's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celularity Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celularity's Days Payable distribution charts can be found below:
* The bar in red indicates where Celularity's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Celularity's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celularity (CELU) has a Days Payable of 315.61 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Celularity and its competitors. This is near median its historical median of 338.47. Over the past decade, Celularity's Days Payable has ranged from 140.39 to 455.85. According to the industry distribution chart, Celularity ranks #156 out of 699 companies in the Biotechnology industry, placing it in the top 22.3%.
Is Celularity's Days Payable too high?
Celularity's current Days Payable of 315.61 is near median its 10-year median of 338.47. Over the past 10 years, this metric has ranged from a low of 140.39 to a high of 455.85. The Biotechnology industry median Days Payable is 112.84. Celularity's value of 315.61 is 179.7% above this industry median. Based on the distribution chart, Celularity ranks #156 out of 699 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Celularity has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Celularity's Days Payable compare to GRTX and BCDA?
According to the Biotechnology industry distribution chart, Celularity ranks #156 out of 699 companies for Days Payable. This places Celularity in the top 22% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.84. Celularity's value of 315.61 is 179.7% above this benchmark. Historically, Celularity's own Days Payable has ranged from 140.39 to 455.85 over the past decade. While the company's 10-year median is 338.47 vs. the industry median of 112.84, Celularity has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celularity's current Days Payable of 315.61 is 179.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Celularity and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celularity's current Days Payable is 315.61, which is near median its own 10-year median of 338.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celularity stock overvalued right now?
Based on GuruFocus' analysis, Celularity (CELU) is currently considered Possible Value Trap. The stock's GF Value™ is $2.28, compared to a current price of $0.75 — trading 67.1% below its estimated fair value. The current Days Payable is 315.61, which is near median its 10-year median of 338.47 and 179.7% above the Biotechnology industry median of 112.84. Celularity's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Celularity (CELU), the current Days Payable is 315.61 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celularity (CELU) Overvalued in 2026?
Based on GuruFocus' analysis, Celularity stock appears to be undervalued.
The current stock price of $0.75 is trading 67.1% below its estimated GF Value™ of $2.28.
GuruFocus considers Celularity to be Possible Value Trap.
Key valuation signals for CELU:
Days Payable: 315.61 (near median its 10-year median of 338.47)
GF Value™: $2.28 vs. price of $0.75 (67.1% below fair value)
Industry Position: 179.7% above the Biotechnology median (#156 of 699)
No single metric tells the full story. See the CELU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
31GF Score
Get the complete analysis for CELU
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CELU has been successfully added to your 
